By combining modern neuroscience with recent advances in gene delivery, the company we have a license agreement with, CombiGene AB, has developed a method shown to suppress epileptic seizures in preclinical studies.
Panion’s focus is on continuing to develop this method into an effective and safe therapy for dogs with epilepsy.
The product in development is based on scientific discoveries made at Lund University and the University of Copenhagen.
In addition, our aim is to in-license and develop other similar assets for the veterinary market.
Panion is a public Swedish company based in Hässleholm, Sweden.
The Panion share has been listed on Spotlight Stock Market since 05/07/2017 under the ticker PANION and is traded through banks and stockbrokers.